Effect of intravenous enalaprilat in moderate and severe systemic hypertension

John C Rutledge, Carlos Ayers, Robert Davidson, Donald DiPette, Gordon Guthrie, Mary Fisher, Skai Schwartz, Ewa Rucinska

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The antihypertensive effect and tolerability of enalaprilat, an intravenously administered angiotensin converting enzyme inhibitor, was studied in 65 patients with moderate or severe hypertension. In this randomized, double-blind study, enalaprilat was compared with placebo in 42 (22 enalaprilat, 20 placebo) moderate hypertensive (diastolic blood pressure [BP] 100 to 114 mm Hg) patients. It was compared with furosemide in 23 (12 enalaprilat, 11 furosemide) severe hypertensive (diastolic BP 115 to 130 mm Hg) patients. Enalaprilat (1.25 or 5.0 mg), placebo (5% dextrose) or furosemide (40 or 80 mg) was given every 6 hours intravenously up to 48 hours. In the moderate hypertension stratum, the mean supine diastolic BP was significantly (p ≤ 0.01) reduced from baseline at all timepoints in the enalaprilat group. These diastolic BP reductions were significantly (p ≤ 0.01) greater in the enalaprilat group than the placebo at 1 to 24 hours (-12 vs -4 mm Hg), with 59% of the patients responding to enalaprilat compared with 30% of the patients responding to placebo. An even greater reduction (p ≤ 0.01) was seen at 25 to 48 hours (-14 vs -7 mm Hg, with 73% enalaprilat vs 58% placebo responders). Significant (p ≤ 0.01) reductions in mean, supine systolic BP were also seen at 1 to 24 hours (-22 vs -2 mm Hg) and 25 to 48 hours (-24 vs -8 mm Hg) during the 48 hours of the double-blind treatment phase in the enalaprilat group compared with placebo. In the severe hypertension stratum, significant (p ≤ 0.05) reductions were noted in the mean supine diastolic BP in the enalaprilat group compared with the furosemide group at 1 to 12 hours (-17 vs -8 mm Hg) with 36 versus 20% of the patients responding and at 13 to 24 hours (-17 vs -8 mm Hg) with 33 versus 11% of the patients responding. No significant difference in systolic BP was seen between enalaprilat and furosemide; however, both enalaprilat and furosemide significantly reduced mean supine systolic BP compared with baseline. Thus, enalaprilat is an effective, well-tolerated agent for the treatment of moderate and severe systemic hypertension.

Original languageEnglish (US)
Pages (from-to)1062-1067
Number of pages6
JournalThe American journal of cardiology
Volume62
Issue number16
DOIs
StatePublished - Nov 15 1988

Fingerprint

Enalaprilat
Blood Pressure
Hypertension
Furosemide
Placebos

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of intravenous enalaprilat in moderate and severe systemic hypertension. / Rutledge, John C; Ayers, Carlos; Davidson, Robert; DiPette, Donald; Guthrie, Gordon; Fisher, Mary; Schwartz, Skai; Rucinska, Ewa.

In: The American journal of cardiology, Vol. 62, No. 16, 15.11.1988, p. 1062-1067.

Research output: Contribution to journalArticle

Rutledge, JC, Ayers, C, Davidson, R, DiPette, D, Guthrie, G, Fisher, M, Schwartz, S & Rucinska, E 1988, 'Effect of intravenous enalaprilat in moderate and severe systemic hypertension', The American journal of cardiology, vol. 62, no. 16, pp. 1062-1067. https://doi.org/10.1016/0002-9149(88)90549-8
Rutledge, John C ; Ayers, Carlos ; Davidson, Robert ; DiPette, Donald ; Guthrie, Gordon ; Fisher, Mary ; Schwartz, Skai ; Rucinska, Ewa. / Effect of intravenous enalaprilat in moderate and severe systemic hypertension. In: The American journal of cardiology. 1988 ; Vol. 62, No. 16. pp. 1062-1067.
@article{e76502ccdb4d40d39cf1da036f898d75,
title = "Effect of intravenous enalaprilat in moderate and severe systemic hypertension",
abstract = "The antihypertensive effect and tolerability of enalaprilat, an intravenously administered angiotensin converting enzyme inhibitor, was studied in 65 patients with moderate or severe hypertension. In this randomized, double-blind study, enalaprilat was compared with placebo in 42 (22 enalaprilat, 20 placebo) moderate hypertensive (diastolic blood pressure [BP] 100 to 114 mm Hg) patients. It was compared with furosemide in 23 (12 enalaprilat, 11 furosemide) severe hypertensive (diastolic BP 115 to 130 mm Hg) patients. Enalaprilat (1.25 or 5.0 mg), placebo (5{\%} dextrose) or furosemide (40 or 80 mg) was given every 6 hours intravenously up to 48 hours. In the moderate hypertension stratum, the mean supine diastolic BP was significantly (p ≤ 0.01) reduced from baseline at all timepoints in the enalaprilat group. These diastolic BP reductions were significantly (p ≤ 0.01) greater in the enalaprilat group than the placebo at 1 to 24 hours (-12 vs -4 mm Hg), with 59{\%} of the patients responding to enalaprilat compared with 30{\%} of the patients responding to placebo. An even greater reduction (p ≤ 0.01) was seen at 25 to 48 hours (-14 vs -7 mm Hg, with 73{\%} enalaprilat vs 58{\%} placebo responders). Significant (p ≤ 0.01) reductions in mean, supine systolic BP were also seen at 1 to 24 hours (-22 vs -2 mm Hg) and 25 to 48 hours (-24 vs -8 mm Hg) during the 48 hours of the double-blind treatment phase in the enalaprilat group compared with placebo. In the severe hypertension stratum, significant (p ≤ 0.05) reductions were noted in the mean supine diastolic BP in the enalaprilat group compared with the furosemide group at 1 to 12 hours (-17 vs -8 mm Hg) with 36 versus 20{\%} of the patients responding and at 13 to 24 hours (-17 vs -8 mm Hg) with 33 versus 11{\%} of the patients responding. No significant difference in systolic BP was seen between enalaprilat and furosemide; however, both enalaprilat and furosemide significantly reduced mean supine systolic BP compared with baseline. Thus, enalaprilat is an effective, well-tolerated agent for the treatment of moderate and severe systemic hypertension.",
author = "Rutledge, {John C} and Carlos Ayers and Robert Davidson and Donald DiPette and Gordon Guthrie and Mary Fisher and Skai Schwartz and Ewa Rucinska",
year = "1988",
month = "11",
day = "15",
doi = "10.1016/0002-9149(88)90549-8",
language = "English (US)",
volume = "62",
pages = "1062--1067",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "16",

}

TY - JOUR

T1 - Effect of intravenous enalaprilat in moderate and severe systemic hypertension

AU - Rutledge, John C

AU - Ayers, Carlos

AU - Davidson, Robert

AU - DiPette, Donald

AU - Guthrie, Gordon

AU - Fisher, Mary

AU - Schwartz, Skai

AU - Rucinska, Ewa

PY - 1988/11/15

Y1 - 1988/11/15

N2 - The antihypertensive effect and tolerability of enalaprilat, an intravenously administered angiotensin converting enzyme inhibitor, was studied in 65 patients with moderate or severe hypertension. In this randomized, double-blind study, enalaprilat was compared with placebo in 42 (22 enalaprilat, 20 placebo) moderate hypertensive (diastolic blood pressure [BP] 100 to 114 mm Hg) patients. It was compared with furosemide in 23 (12 enalaprilat, 11 furosemide) severe hypertensive (diastolic BP 115 to 130 mm Hg) patients. Enalaprilat (1.25 or 5.0 mg), placebo (5% dextrose) or furosemide (40 or 80 mg) was given every 6 hours intravenously up to 48 hours. In the moderate hypertension stratum, the mean supine diastolic BP was significantly (p ≤ 0.01) reduced from baseline at all timepoints in the enalaprilat group. These diastolic BP reductions were significantly (p ≤ 0.01) greater in the enalaprilat group than the placebo at 1 to 24 hours (-12 vs -4 mm Hg), with 59% of the patients responding to enalaprilat compared with 30% of the patients responding to placebo. An even greater reduction (p ≤ 0.01) was seen at 25 to 48 hours (-14 vs -7 mm Hg, with 73% enalaprilat vs 58% placebo responders). Significant (p ≤ 0.01) reductions in mean, supine systolic BP were also seen at 1 to 24 hours (-22 vs -2 mm Hg) and 25 to 48 hours (-24 vs -8 mm Hg) during the 48 hours of the double-blind treatment phase in the enalaprilat group compared with placebo. In the severe hypertension stratum, significant (p ≤ 0.05) reductions were noted in the mean supine diastolic BP in the enalaprilat group compared with the furosemide group at 1 to 12 hours (-17 vs -8 mm Hg) with 36 versus 20% of the patients responding and at 13 to 24 hours (-17 vs -8 mm Hg) with 33 versus 11% of the patients responding. No significant difference in systolic BP was seen between enalaprilat and furosemide; however, both enalaprilat and furosemide significantly reduced mean supine systolic BP compared with baseline. Thus, enalaprilat is an effective, well-tolerated agent for the treatment of moderate and severe systemic hypertension.

AB - The antihypertensive effect and tolerability of enalaprilat, an intravenously administered angiotensin converting enzyme inhibitor, was studied in 65 patients with moderate or severe hypertension. In this randomized, double-blind study, enalaprilat was compared with placebo in 42 (22 enalaprilat, 20 placebo) moderate hypertensive (diastolic blood pressure [BP] 100 to 114 mm Hg) patients. It was compared with furosemide in 23 (12 enalaprilat, 11 furosemide) severe hypertensive (diastolic BP 115 to 130 mm Hg) patients. Enalaprilat (1.25 or 5.0 mg), placebo (5% dextrose) or furosemide (40 or 80 mg) was given every 6 hours intravenously up to 48 hours. In the moderate hypertension stratum, the mean supine diastolic BP was significantly (p ≤ 0.01) reduced from baseline at all timepoints in the enalaprilat group. These diastolic BP reductions were significantly (p ≤ 0.01) greater in the enalaprilat group than the placebo at 1 to 24 hours (-12 vs -4 mm Hg), with 59% of the patients responding to enalaprilat compared with 30% of the patients responding to placebo. An even greater reduction (p ≤ 0.01) was seen at 25 to 48 hours (-14 vs -7 mm Hg, with 73% enalaprilat vs 58% placebo responders). Significant (p ≤ 0.01) reductions in mean, supine systolic BP were also seen at 1 to 24 hours (-22 vs -2 mm Hg) and 25 to 48 hours (-24 vs -8 mm Hg) during the 48 hours of the double-blind treatment phase in the enalaprilat group compared with placebo. In the severe hypertension stratum, significant (p ≤ 0.05) reductions were noted in the mean supine diastolic BP in the enalaprilat group compared with the furosemide group at 1 to 12 hours (-17 vs -8 mm Hg) with 36 versus 20% of the patients responding and at 13 to 24 hours (-17 vs -8 mm Hg) with 33 versus 11% of the patients responding. No significant difference in systolic BP was seen between enalaprilat and furosemide; however, both enalaprilat and furosemide significantly reduced mean supine systolic BP compared with baseline. Thus, enalaprilat is an effective, well-tolerated agent for the treatment of moderate and severe systemic hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0023701281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023701281&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(88)90549-8

DO - 10.1016/0002-9149(88)90549-8

M3 - Article

C2 - 2847522

AN - SCOPUS:0023701281

VL - 62

SP - 1062

EP - 1067

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 16

ER -